This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Salix Pharma to Acquire Santarus

NEW YORK (TheStreet) -- Gastrointestinal drugmaker Salix Pharmaceuticals (SLXP) announced it will acquire smaller biopharmaceutical company Santarus (SNTS) in a deal worth $2.6 billion. The purchase agreement of $32 a share provides a 39% premium to Santarus' average 30-day closing price. The transaction is expected to be finalized by the first quarter 2014.

In response, Salix shares gained 9.4% to $77.99 and Santarus soared 37.2% to $31.86 in after-hours trading.

Salix said the acquisition will help position the combined entity as the largest U.S. gastroenterology-focused drug company with annual product revenue of $1.3 billion.

"We are extremely pleased with the Santarus acquisition, which is transformative for Salix both commercially and financially, fulfilling many of our strategic needs, while providing immediate and significant accretion in 2014 and beyond," said Salix CEO Carolyn Logan in a statement.

As part of the deal, the companies will merge salesforces, combine product portfolios and expand the number of health care prescribers in their database. The deal's revenue diversification will benefit its bottom line as no one product is expected to bring in more than 50% of total revenue (this, as Ariad Pharmaceuticals learnt late October, is an important consideration). 

After the bell, San Diego-based Salix reported third-quarter earnings of 89 cents a share on $238.2 million in revenue. Earnings came in 3 cents higher than analysts surveyed by Yahoo! Finance had expected though revenue, a 29% increase on a year earlier, missed estimates by $1.5 million.

Investment banking firm Jefferies (JEF) acted as the sole financial adviser for the transaction. 

--Written by Keris Alison Lahiff.

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,172.68 -107.06 -0.62%
S&P 500 1,994.29 -16.11 -0.80%
NASDAQ 4,527.6890 -52.10 -1.14%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs